Essential Thrombocythemia Possible Cause of Ischemic Cerebrovascular Disease: A Case Report

Essential Thrombocythemia Possible Cause of Ischemic Cerebrovascular Disease: A Case Report

Essential thrombocythemia (ET) is a rare, chronic myeloproliferative neoplasm characterized by the overproduction of platelets. ET is of significant clinical importance due to thrombotic and hemorrhagic cerebrovascular disease. The JAK2 V617F mutation has been identified in approximately 50-60% of E...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) Vol. 16; no. 10; p. e71846
Main Authors: Korucu, Ibrahim, Ciril, Muhammed Fatih
Format: Journal Article
Language:English
Published: United States Cureus 19-10-2024
Subjects:
Neurology
cerebrovascular disease
chronic myeloproliferative neoplasms
jak2 v617f mutation
vascular neurology
essential thrombocythaemia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Essential thrombocythemia (ET) is a rare, chronic myeloproliferative neoplasm characterized by the overproduction of platelets. ET is of significant clinical importance due to thrombotic and hemorrhagic cerebrovascular disease. The JAK2 V617F mutation has been identified in approximately 50-60% of ET cases. Our case report: a 41-year-old male presented to the hospital with a one-day history of vertigo, ataxic gait, and vomiting. The patient was diagnosed with ET at an external center two years ago. The JAK2 V617F mutation was detected. He regularly uses acetylsalicylic acid 100 mg per day. Magnetic resonance imaging (MRI) showed an acute infarction involving the bilateral cerebellar hemisphere, thalamic area, and right occipital area. Computed Tomography Angiography showed that no significant stenosis was detected in major branches. The patient was diagnosed with ischemic cerebrovascular disease for ET. Antiplatelet therapy was started with acetylsalicylic acid 100 mg and clopidogrel 75 mg once a day. With the recommendation of hematology, cytoreductive treatment, hydroxyurea 1000 mg twice a day, was started. The patient's complaints were resolved at the end of the second day, and the patient with minimal ataxia was discharged with recommendations. Patients with ET should be aware of ischemic cerebrovascular disease and consider antiplatelet and cytoreductive treatment options.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.71846